Sharon George, DO
Family Medicine · Warren, OHNPI 1942292461
Payments from drug & device makers
Across 106 payments — averaging $161.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$15K
- Avanir Pharmaceuticals, Inc.$191
- Vanda Pharmaceuticals Inc.$182
- Novo Nordisk$143
- Otsuka America Pharmaceutical, Inc.$132
- Amarin Pharma, Inc.$113
- plus $917 from 22 others
What the payments were for
- Consulting fees$15,45090%
- Food & beverage$1,67810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 11 | $15,450 |
| Avanir Pharmaceuticals, Inc. | 14 | $191 |
| Vanda Pharmaceuticals Inc. | 7 | $182 |
| Novo Nordisk | 10 | $143 |
| Otsuka America Pharmaceutical, Inc. | 8 | $132 |
| Amarin Pharma, Inc. | 1 | $113 |
| Lundbeck LLC | 5 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $105 |
| Bayer | 5 | $95 |
| AstraZeneca | 6 | $91 |
| Novartis | 5 | $89 |
| Sunovion Pharmaceuticals Inc. | 4 | $69 |
| Evoke Pharma, Inc. | 3 | $49 |
| Boston Scientific | 1 | $43 |
| Amgen | 2 | $29 |
| Johnson & Johnson | 2 | $28 |
| Merck | 2 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Pfizer | 2 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$113
How this compares
$17,128 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 31 | $140,794 |
| EliquisApixaban | 305 | $97,039 |
| Invega SustennaPaliperidone Palmitate | 14 | $43,856 |
| NuedextaDextromethorphan Hbr/Quinidine | 32 | $32,667 |
| JardianceEmpagliflozin | 63 | $28,958 |
| ZenpepLipase/Protease/Amylase | 17 | $28,385 |
| XareltoRivaroxaban | 81 | $26,629 |
| GemtesaVibegron | 66 | $22,749 |
| JanuviaSitagliptin Phosphate | 46 | $22,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,690 |
| XifaxanRifaximin | 14 | $14,410 |
| EntrestoSacubitril/Valsartan | 34 | $14,194 |
| MyrbetriqMirabegron | 46 | $12,914 |
| Budesonide | 70 | $10,319 |
| Formoterol Fumarate | 30 | $9,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $18 | $140,79431 claims |
| PfizerEliquis | $23 | $97,039305 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $28 | $70,48595 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $191 | $32,66732 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $20 | $22,74966 claims |
| MerckJanuvia | $27 | $22,42746 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $105 | $14,41014 claims |
| NovartisEntresto | $89 | $14,19434 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $12,91446 claims |
| AbbVieFetzima | $12 | $7,03427 claims |
| AstraZenecaSymbicort | $91 | $5,63324 claims |
| Sanofi-aventis U.S. LLCLantus | $13 | $5,21937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Warren
- Jason RupekaWarren$77K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.